6th Digital Pharma & Life Sciences Conference 2011

22 February 2011, Wiesbaden, Germany.
For the sixth time Microsoft and its partners will be holding the Digital Pharma & Life Sciences conference. The lecture event and exhibition is aimed at the pharmaceutical, chemical and life sciences industries, showing current projects and innovative technologies that support greater sustainability, cost efficiency and competitiveness in and through IT.

IT has become a critical competitive factor as an instrument for sustainable climate and environmental protection. The framework is set by international initiatives by industries and governments: for example more than 500 investors request global listed companies to report their CO2 relevant business data through the Carbon Disclosure Project (CDP) from the UK. Global initiatives for Green Chemistry such as the conventions from Stockholm, Rotterdam and Basel, the OECD and the regulatory authorities of developed countries are working to create global standards for sustainable risk and chemicals management.

For this reason, the Digital Pharma & Life Sciences conference 2011 is focussing on the topics "Green IT – Green Chemistry". With the focus on "Green in IT", experts will discuss latest developments of Green IT technologies on the basis of recent successful projects in order to make processes more efficient, save resources and energy and thereby reduce costs. These include concepts for IT virtualization in controlling chemical production or cloud computing for pharmaceutical research.

The "Green through IT" presentations will show pioneering Green Chemistry projects that ensure sustainability in production, research and development and overall global supply chains. Leading companies from the chemical, pharmaceutical and life sciences industries demonstrate how they coordinate production and logistics processes better through intelligent technologies, plan forward-looking and therefore design initiatives for more economically measurable sustainability.

The conference takes place on 22nd February 2011 in the Kurhaus Wiesbaden and is aimed at decision makers and experts from the fields of IT and business management, research and development, business development management, product management, production, quality management, sales and controlling.

During the accompanying exhibition, the partners of the Digital Pharma & Life Sciences initiative will show latest IT technologies and reference projects. On the eve of the conference on 21st February 2011, an exclusive dinner will take place with all the speakers, conference participants and partners of the initiative.

Further information for registration, the agenda and logistic details are available at:
http://www.digitalpharma.de

Most Popular Now

Top 20 breaking World Pharma News of 2017

We are proud to announce the top 20 most popular breaking World Pharma News from 2017. Have a wonderful 2018 new(s) year filled with health, happiness, and spectacular su...

Novartis advances head-to-head superiority trials …

Novartis announced today the initiation of SURPASS, a head-to-head clinical trial of Cosentyx® (secukinumab) versus proposed biosimilar adalimumab** in ankylosing spondyl...

Diabetes drug 'significantly reverses memory loss…

A drug developed for diabetes could be used to treat Alzheimer's after scientists found it "significantly reversed memory loss" in mice through a triple method of action...

Sandoz regulatory submission for proposed biosimil…

Sandoz, a Novartis division and the global leader in biosimilar medicines, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics Licen...

Zika remains a research and public health challeng…

Since 2016, when Zika was declared by the World Health Organization as a public health emergency of international concern, the virus has become established in more than 8...

Try exercise to improve memory, thinking

For patients with mild cognitive impairment, don't be surprised if your health care provider prescribes exercise rather than medication. A new guideline for medical pract...

New research paper shows that AstraZeneca has achi…

In a research paper published today by Nature Reviews Drug Discovery(1), AstraZeneca's IMED Biotech Unit documents a more than four-fold improvement in R&D productivity f...

Dirt-dwelling microbe produces potential anti-mela…

A type of soil-dwelling bacterium produces molecules that induce death in melanoma cells, research at Oregon State University shows. The molecule is a secondary metabolit...

Novartis Kisqali® received FDA Breakthrough Therap…

Novartis today announced Kisqali® (ribociclib) received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pr...

FDA approves first treatment for breast cancer wit…

The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast can...

Berry gives boost to cervical cancer therapy

According to the Centers for Disease Control and Prevention, approximately 12,000 women in the United States are diagnosed with cervical cancer each year. One of the most...

Novartis appoints Elizabeth Barrett as Oncology He…

Novartis announced today that Elizabeth (Liz) Barrett, currently Global President Oncology at Pfizer, Inc., has been appointed CEO Novartis Oncology and a member of the E...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]